Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain
MicrobiologyOpen · 2026-06 · 15 (3)
DOI: 10.1002/mbo3.70299 ↗Kurz gefasst
Fachartikel in der Zeitschrift MicrobiologyOpen, online erschienen am 04.05.2026. Verfasst von Nasser Alotaiq und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, Spike Glycoprotein, Coronavirus, Antiviral Agents, Peptides. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).
Abstract (Originalsprache)
Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) remains a significant global health threat, necessitating the development of effective antiviral therapeutics. Targeting the heptad repeat 2 (HR2) domain of the MERS‐CoV spike protein offers a promising strategy to inhibit viral fusion and entry into host cells. This study investigates a panel of antiviral peptides (AVPs), focusing on Griffithsin, Brevinin‐2, and CCL20, to evaluate their potential as fusion inhibitors against the HR2 domain. Employing comprehensive computational approaches, including molecular docking, molecular dynamics (MD) simulations, and MM/PBSA binding free energy calculations, we characterized the peptide‐protein interactions and stability of these AVPs in complex with HR2. Our results demonstrate that Griffithsin, Brevinin‐2, and CCL20 exhibit stronger binding affinities (− 213.69, −168.83, and −165.17 kcal/mol, respectively) compared to the standard inhibitor Peptide‐6 (− 49.73 kcal/mol). MD simulations reveal stable complexes and indicate disruption of critical hydrogen bonds in the Ile1255–Gln1271 region of HR2, essential for six‐helix bundle formation and viral fusion. Physicochemical analyses further suggest favorable stability, half‐life, and low hemolytic potential, supporting their suitability as therapeutic candidates. These findings align with prior studies highlighting the broad‐spectrum antiviral activity of Griffithsin and validate the therapeutic promise of Brevinin‐2 and CCL20. While this computational investigation lays the groundwork, further in vitro and in vivo validation and optimization of pharmacokinetics and delivery are necessary for clinical development. This study advances the rational design of peptide‐based fusion inhibitors targeting MERS‐CoV and provides valuable insights into antiviral strategies against emerging coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.
- Laboratory of Analytical and Molecular Chemistry, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, Morocco.
ORCID-Profile: Nasser Alotaiq, Doni Dermawan, Samir Chtita
Förderung
- Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)
Zitieren
APA
Alotaiq, N., Dermawan, D., & Chtita, S. (2026). Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain. MicrobiologyOpen, 15(3). https://doi.org/10.1002/mbo3.70299
Vancouver
Alotaiq N, Dermawan D, Chtita S. Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain. MicrobiologyOpen. 2026;15(3). doi:10.1002/mbo3.70299
BibTeX
@article{Alotaiq2026,
author = {Alotaiq, Nasser and Dermawan, Doni and Chtita, Samir},
title = {Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain},
journal = {MicrobiologyOpen},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/mbo3.70299}
}
EUVIMED